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Abstract
Fragile X syndrome is caused by the absence of the Fragile X Mental Retardation Protein (FMRP), an RNA-binding protein.
FMRP is associated with messenger RiboNucleoParticles (mRNPs) present in polyribosomes and its absence in neurons leads
to alteration in synaptic plasticity as a result of translation regulation defects. The molecular mechanisms by which FMRP
plays a role in translation regulation remain elusive. Using immunoprecipitation approaches with monoclonal Ab7G1-1 and
a new generation of chicken antibodies, we identified Caprin1 as a novel FMRP-cellular partner. In vivo and in vitro evidence
show that Caprin1 interacts with FMRP at the level of the translation machinery as well as in trafficking neuronal granules.
As an RNA-binding protein, Caprin1 has in common with FMRP at least two RNA targets that have been identified as
CaMKIIa and Map1b mRNAs. In view of the new concept that FMRP species bind to RNA regardless of known structural
motifs, we propose that protein interactors might modulate FMRP functions.
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Introduction
Fragile X syndrome (FXS) is caused by the absence of
expression of the Fragile X Mental Retardation Protein (FMRP)
[1–3]. This RNA-binding protein widely expressed in mammalian
tissues [4] is particularly abundant in neurons [5], and is a
component of messenger ribonucleoprotein complexes (mRNP)
associated with brain polyribosomes [6–8]. Its presence within the
translational apparatus suggests that it is involved in control of
mRNAs. In addition to its main location in neuronal cell body,
FMRP is also found in growth cones and dendritic spines
suggesting that it plays also a role in regulating local protein
synthesis in micro-domains [3,9]. In between the soma and these
micro-domains, FMRP is found travelling in granules that contain
packed mRNAs to be delivered at these micro-sites. The current
concept is that absence of FMRP induces translation dysregulation
and defects in mRNA transport that are thought to alter local
protein synthesis essential for synaptic development and matura-
tion [3,10–12]. One of the consequences of the lack of FMRP is
the presence of abnormal looking immature and supernumerary
neuronal dendritic spines in the brains of fragile X patients
[13,14], that ultimately lead to mental retardation in FXS patients.
FMRP has been reported to associate with several hundred of
different mRNAs as detected by co-immunoprecipitation [15],
antibody positioned RNA amplification (APRA) [16] and in vitro
by affinity capture [17] and cDNA-SELEX [18]. More recently,
using high-throughput sequencing of RNAs isolated by cross-
linking immunoprecipitation (HITS-CLIP), Darnell et al. [19]
succeeded to identify those mRNAs in direct contact with FMRP
that are thought to be the bona fide targets. In addition to its affinity
to RNA, FMRP has the ability to interact with a series of proteins
either directly or indirectly [20]. These interacting proteins might
modulate FMRP functions by inducing structural changes in its
conformation [21]. Two regions in FMRP, at the NH2- and at the
COOH-termini have been reported to mediate interactions with
protein partners. Interactors such as FXR1P, FXR2P, NUFIP, 82-
FIP, CYFIP1 and CYFIP2 bind the NH2-terminal region
(reviewed in [2]), while MSP-58, KifC3, Ran-BPM and SMN
have affinities to regions situated at the C-terminus [22–25]. Other
proteins such as nucleolin, YB-1/p50, Pur-a, myosin Va, kinesin,
RNG140 and Stauffen have been detected in complexes
containing FMRP either by immunoprecipitation or immuno-
staining approaches [26–29], but it is not known whether they
interact physically with FMRP.
In search for new proteins that interact directly with FMRP in
neurons, we identified Caprin1, an RNA-binding protein, as a
novel FMRP partner. Interestingly, Caprin1 shares several
features with FMRP and has been also proposed to control
translation in neurons [30,31].
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Monoclonal Antibody 7G1-1 Recognizes Two Different
RNA-binding Proteins
In an effort to identify new proteins that interact with FMRP,
we thought to isolated the complex containing FMRP using an
immunoprecipitation approach. Brain lysates prepared from WT
and from Fmr1
2/2 KO2 mice [32] were immunoprecipitated
with mAb7G1-1 [15,33] under conditions as close as possible to
those described [15] and the retained material analyzed by
immunoblotting using mAb1C3. In agreement with Brown et al.
[15], we detected mFMRP in immunoprecipitates from wild type
C57BL/6J brain, while, as expected, no corresponding signals
were present in extracts from Fmr1
2/2 KO2 mice (Figure 1A).
However, when mAb1C3 was substituted by mAb7G1-1 for
immunoblotting, a clear additional band at <116 kDa was
constantly observed (Figure 1A). Surprisingly, this band was also
present in immunoprecipitates from brain extracts prepared from
the Fmr1
2/2 KO2 mice. Pre-incubation of mAb7G1-1 with the
epitope peptide corresponding to mFMRP 354-
KHLDTKENTHFSQPN-368 was effective in completely inhib-
iting its immunoprecipitation (Figure 1A) as previously reported
[15]. Unexpectedly, we also observed that preincubation of
mAb7G1-1 with the peptide resulted in the disappearance of
the 116 kDa band, even in the case of the Fmr1
2/2 KO2 extracts.
Having shown that mAb7G1-1 immunoprecipitates both
mFMRP and the unknown protein p116, we further tested the
behaviour of mAb7G1-1 by immunoblot analyses. Using mAb1C3
for immunoblotting, the expected picture (Figure 1B) of mFMRP
and its isoforms was revealed in 3T3 cells. In contrast, no signals
could be observed in STEK cells devoid of FMRP [34]. On the
other hand, in immunoblotting with mAb7G1-1, the antibody
clearly reacted with both mFMRP and p116 in 3T3 extracts, and
only with p116 in STEK extracts. In repeated analyses, an
additional band was also detected at ,65 kDa (Figure 1B
indicated by a star). This peptide corresponds to a cleavage
product of p116 as shown below. All signals were abolished when
the hybridoma supernatant was pretreated with the epitope
peptide, as was the case for the immunoprecipitation analyses (see
above). Recognition of both mFMRP and p116 by mAb7G1-1 was
resistant to washes in 4 M urea (Figure 1B), indicating its strong
affinity to both protein targets. To rule out for the presence of a
contaminating antibody, we affinity-purified the anti-mFMRP
using recombinant mFMRP and the resulting purified IgG still
reacted with both proteins, while no signal could be revealed using
the IgG depleted supernatants. Identical results were obtained
using purified 7G1-1 obtained from Jennifer Darnell (results not
Figure 1. mAb7G1-1 detects mFMRP and Caprin1. A) Immunoprecipitation analyses of WT and KO2 mouse brain extracts with mAb7G1-1
followed by immunoblotting with mAb1C3 (left panel in A) or with mAb7G1-1 (right panel in A). In addition to mFMRP, a clear band at 116 kDa is
detected in WT immunoprecipitates. A similar band is also detected in KO2 extracts. Both bands are absent when immunoprecipitation is performed
in the presence of the epitope peptide KHLDTKENTHFSQPN. B) Immunoblot analyses with mAb7G1-1 of 3T3, STEK and HeLa cell extracts. While
mAb3C1 detects only mFMRP in 3T3 extracts, mAb7G1-1 reacts with both mFMRP and p116. An additional weak band is also detected in both
extracts at 65 kDa (indicated by a star). mAb7G1-1 does not react with hFMRP from HeLa extracts, but recognizes p116. Note the presence of the
additional band that migrates slightly above 65 kDa in human HeLa extracts (double star). C) Extracts from STEK cells were immunoprecipitated with
mAb7G1-1. Immunoblot analyses with mAb1C3 reveal that mFMRP is indeed absent, while mAb7G1-1 reacts with p116. The Coomassie brillant blue
stained band at 116 kDa was excised and analyzed by mass spectrometry and was identified as Caprin1. Immunoblot analyses with rabbit antisera
raised against hCaprin1 confirmed the nature of p116 as Caprin1. D) In vitro translated
35S-labeled Caprin1 is immunoprecipitated by mAb7G1-1. E)
Recombinant GST-Caprin1 isolated on Glutathione-Sepharose beads is revealed with anti-Caprin1 IgG in immunoblot analyses. Note the presence of
the minor truncated band at ,95 kDa. F) Structural comparisons between FMRP and Caprin1. WT and KO: wild type C57BL/6J and Fmr1
2/2KO2 mice,
respectively. IP: immunoprecipitation; IB: immunoblot; Cont: control; HC: IgG heavy chains; AP: affinity purified; AD: affinity depleted; AR:
autoradiography.
doi:10.1371/journal.pone.0039338.g001
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analyzed. The rational for using HeLa extracts was that mAb7G1-
1 has been reported not to react with hFMRP [15]. As shown in
Figure 1B, indeed mAb7G1-1 does not pick up hFMRP, however
the p116 signal still remained. We noted that the migration of the
65 kDa band in human cells was slightly slower compared to
mouse (double star), as also observed for normal and X-fragile
human lymphoblastoid cells (data not shown).
Although 7G1-1 is a monoclonal antibody, we hypothesized
that in addition to mFMRP, it could cross-react with a yet
unknown protein. To test this hypothesis, extracts prepared from
STEK cells were immunoprecipitated with mAb7G1-1 and the
eluted material analyzed by immunoblotting. As expected no
mFMRP band could be detected after reaction with mAb1C3
while, again a clear and single band of approximately 116 kDa
was visualized after reaction with mAb7G1-1 (Figure 1C). A band
of similar apparent molecular weight was present after Coomassie
brilliant blue staining of a SDS-PAGE. To identify this protein, the
stained band was excised from the gel and submitted to mass
spectrometry. Using the Scaffold 3 search program, the 22 trypsin
generated polypeptides were shown to correspond to mouse
Caprin1 (Cytoplasmic activation- and proliferation-associated
protein 1) [30]. To confirm the MS identification, two different
anti-sera directed against Caprin1 were used and both strongly
reacted with p116 in immunoblot analyses.
To further confirm that p116 is Caprin1, in vitro translated
35S-
labeled Caprin1 was immunoprecipitated with mAb7G1-1 and
analyzed by SDS-PAGE. Autoradiography of the dried gel
revealed a strong labeled band at 116 kDa while no signals were
observed in immunoprecipitates with mAb1C3 (Figure 1D). In
addition to the major 116 kDa signal, several bands were detected
around 60–70 kDa corresponding to in vitro synthesized truncated
Caprin1 forms (see below). However, using this approach, it was
not possible to determine whether the p65 form shown in
Figure 1B corresponded to a Caprin1 truncated form or to a
normal isoform. We therefore prepared recombinant GST-
Caprin1 that was used in an affinity assay with Glutathione-
Sepharose beads. The retained material was eluted and analyzed
by immunoblotting using anti-Caprin1 IgG. The results showed
clearly that the major band detected around 140 kDa correspond-
ed to GST-Caprin1 and that the minor band around 95 kDa to
GST-p65 (Figure 1E). These results indicate that p65 is a
truncated form of Caprin1 and does not arise from a spliced
variant since in vitro translated and bacterial recombinant GST-
Caprin1 were used in these assays.
One possible explanation of the recognition of both mFMRP
and Caprin1 by mAb7G1-1 would have been that the original
hybridoma 7G1-1 secreting cells were contaminated by an anti-
Caprin1 hybridoma. In an attempt to purify the anti-FMRP
hybridoma, we subcloned the original 7G1-1 cells and obtained 14
single-cell colonies. All subclones secreted antibodies of IgG2b
type (as for the original clone confirmed by the Developmental
Studies Hybridoma Bank, University of Iowa, USA) that reacted
simultaneously with both mFMRP and Caprin1.
Caprin1 is a Novel mFMRP-interacting Protein
The results reported above clearly demonstrate that mAb7G1-1
reacts simultaneously with two different proteins, namely FMRP
and Caprin1. While it is not exceptional that monoclonal
antibodies might not be exclusive to a single protein, the present
situation was intriguing. Indeed Costa et al. [35] have reported in
Drosophila that immunoprecipitates of Orb, the ortholog of the
vertebrate CPEB1 (Cytoplasmic Polyadenylation Element Binding
protein-1), contain dFMRP, plus the ortholog of Caprin1 and Rin,
the Drosphila ortholog of the vertebrate RNA-binding protein
G3BP-1, the heterodimeric partner of Caprin1 in vertebrates.
Similarly to FMRP, Caprin1 is an RNA-binding protein that is
highly expressed in brain and is thought to play a role in local
translation control in neurons [30,31]. In addition to these
features, Caprin1 shares with FMRP a series of similar charac-
teristics such as a coiled-coil domain, a nuclear localization signal
(NLS), a nuclear export signal (NES), an E-, a Q- rich regions that
are present in RNA-binding proteins [36,37]. Finally, an RG-rich
region is present at the C-terminus of the protein (Figure 1F).
Altogether these intriguing observations prompted us to further
investigate whether Caprin1 is a new FMRP interactor.
a) Immunoprecipitation studies. Based on the results
reported above, we concluded that the mAb7G1-1 was not a
reliable tool to immunoprecipitate FMRP to study its associated
proteins. We therefore decided to obtain new antibodies to FMRP
in chicken, since due to the phylogenetic distance between birds
and mammals, there are more antigenic differences between
mammal and chicken FMRP, and thus chickens would make more
antibodies against many non conserved epitopes. His6X-recom-
binant hFMRP was prepared and injected in a series of chickens
and the IgY isolated from eggs. Of the several preparations of IgY
obtained, #C10 was retained and used throughout the present
study.
To test whether IgY#C10 effectively immunoprecipitates
FMRP, whole brain lysates were prepared from WT and from
Fmr1 KO2 mice and subjected to immunoprecipitation under
different conditions. The results showed that a high salt condition
was required to quantitatively immunoprecipitate mFMRP in
agreement with Brown et al. [15]. A 15–20 fold increase in the
recovery of immunoprecipitated mFMRP was observed when
lysates were treated at 400 mM NaCl as compared to 150 mM
NaCl (Figure 2A). However, no difference in mFMRP recovery
was observed whether the lysates were treated with EDTA or
MgCl2 (not shown). When immunoprecipitates obtained with
IgY#C10 were tested in immunoblots with mAb7G1-1, mFMRP
was detected in WT extracts together with Caprin1. This was
further confirmed by immunoblotting with an antiserum directed
against Caprin1 that revealed the p116 band. To confirm that
Caprin1 co-immunoprecipitates with mFMRP, the reverse
immunoprecipitation was carried out with an anti-Caprin1
antibody. Using the same sequence of analyses applied to the
immunoprecipitated materials with IgY#C10, mFMRP was
detected confirming the presence of the two proteins (Figure 2B).
It has been reported previously that certain batches of
mAb7G1-1 immunoprecipitate, in addition to FMRP, two other
proteins [38]. These proteins were identified as Ago2 and p137,
and the authors concluded that mAb7G1-1 carries an anti-Ago2
activity. First, it should be recalled that p137 glycosylpho-
sphatidylinositol-anchored membrane protein is in fact Caprin1
(http://www.genecards.org/cgi-bin/carddisp.
pl?gene=CAPRIN1; see also ref. 30). Having resolved the first
part of the puzzle, we then wished to determine whether
mAb7G1-1 has an additional intrinsic anti-Ago2 activity. Immu-
noprecipitated proteins obtained from WT and KO brain lysates
were analyzed simultaneously for the presence of FMRP, Caprin1
and Ago2 on a single membrane, using the Odyssey Infrared
Imaging System from LI-COR (Figure 2C). mAb7G1-1 was
revealed with secondary antibodies IR-Dye 700 (red) and rabbit
antibodies against Ago2 with IR-Dye 800 (green). Using the
700 nm single channel detecting the red fluorescence emission, we
observed that mAb7G1-1 immunoprecipitates only FMRP and
Caprin1, in agreement with the results presented in Figure 1A.
Using simultaneously the two channels 700 and 800 nm, an
FMRP-Caprin1 Interactions
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corresponding to Ago2 (Figure 2C). These results clearly indicate
that Ago2 is present in immunoprecipitates obtained with
mAb7G1-1, however the absence of red signals at 95 kDa rules
out the possibility that mAb7G1-1 has an anti-Ago2 activity. In
addition, direct immunoblot analyses with mAb7G1-1 using the
single channel 7000, revealed only 2 bands corresponding to
Caprin1 and FMRP, while Ago2 had to be detected by an
additional anti-Ago2 antibody shown in green at channel 800
(Figure 2C). These analyses prove that mAb7G1-1 does not carry
an anti-Ago2 activity and indicate that the latter is co-precipitating
with Caprin1. In a last set of analyses (Figure 2D), Ago2 signals co-
precipitating with Caprin1 were abolished when the immunopre-
cipitations were conducted in the presence of the epitope peptide
(see Figure 1A) indicating that Ago2 precipitation is dependent on
Caprin1. Altogether, these results indicate that Ago2 is present in a
complex containing Caprin1, however it is not known whether the
two proteins intercact physically. Work is in progress to determine
whether Caprin1, and at the same time FMRP, binds to Ago2
directly or indirectly.
b) Mapping of Caprin1-FMRP interactions. To verify
whether FMRP interacts physically with Caprin1, we performed a
series of pull-down assays using hFMRP and hCaprin1 full-length
proteins, as well as their truncated and deleted forms. These
proteins were produced and labeled with [
35S-methionine] by
in vitro transcription-translation using the rabbit reticulocyte lysate.
Full length hFMRP and hCaprin1 were produced in bacteria as
glutathione S-transferase (GST) fusion proteins and immobilized
on glutathione-Sepharose beads. Immobilized GST-hCaprin1 was
incubated with either in vitro translated hFMRP and its truncated
and deleted versions, or with luciferase as a negative control
(Figure 3A). In parallel, immobilized GST-hFMRP was incubated
with in vitro translated Caprin1 and its truncated and deleted
versions (Figure 3B). The results of these pull-down assays show
that the FMRP region spanning amino acids 427–442 is necessary
for binding to Caprin1 (Figure 3C). On the other hand, Caprin1
region at amino acids 231–245 is necessary for interaction with
FMRP. To ascertain that residues 427–442 in FMRP are involved
in the mutual interaction, we tested whether FMRP lacking the
NES domain (D423–441) binds to Caprin1. The results presented
in Figure 3D clearly indicate that amino acids 424–440 are
required for Caprin1 recognition.
To verify that the interaction between FMRP and Caprin1 was
direct and not RNA-dependant, all GST-pulldown assays were
also performed in the presence of RNase A. This treatment did not
alter the results presented above, indicating that the interaction
occurs at the protein-protein level (data not shown). We also tested
the interaction of hFMRP with GST-Caprin1 at 400 mM NaCl to
mimic the conditions used in the immunoprecipitation assays
described above (see Figure 2) and observed that the in vitro
Figure 2. mFMRP co-immunoprecipitates with Caprin1. Total
brain extracts from WT and KO mice were subjected to immunopre-
cipitation with IgY#C10 (A) and anti-Caprin1 IgG (B) and the eluted
proteins were analyzed by immunoblotting using mAb1C3, mAb7G1
and anti-Caprin1 IgG. Note that a high salt concentration was necessary
to immunoprecipitate mFMRP in association with Caprin1. C) mAb7G1-
1 has no anti-Ago2 intrinsic activity, however Ago2 is co-immunopre-
citating with Caprin1 (left panels) as detected using the Odyssey
Infrared Imaging System. In the right panels are shown the results
proving that mAb7G1-1 does not possess an anti-Ago2 activity as
detected by direct immunoblot analyses. Membranes were either
scanned at 700 nm or simultaneously at 700 plus 800 nm. D) The
epitope peptide (see Figure 1A) abolishes co-precipitation of Ago2 with
Caprin1.
doi:10.1371/journal.pone.0039338.g002
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out the possibility that the interaction is mediated by a third factor
present in the rabbit reticulocyte lysate, we used a pull-down assay
based on bacterial recombinant proteins. Recombinant His-
mFMRP was incubated with glutathione-Sepharose beads loaded
either with GST-Luciferase or with GST-hCaprin1. After washing
in physiological buffer containing 0.1% SDS, the material bound
to the beads was desorbed and analyzed by immunoblotting using
mAb1C1 against FMRP. The results presented in Figure 3 F
clearly indicate that the interaction of FMRP and Caprin1 is
direct.
mFMRP Co-sediments with Caprin1 in Polyribosomes and
Co-localizes in Trafficking Granules
a) mFMRP and Caprin1 are present in polyribosomal
mRNP complexes. It is well established that FMRP is present
in mRNP complexes associated with heavy sedimenting polyribo-
somes prepared from total brain [7,8]. Since Caprin1 is strongly
expressed in brain and has been reported to be a complement of
the translation machinery [30,31] we asked whether its distribu-
tion is similar to mFMRP. Brain polyribosomes were prepared as
previously described and analyzed by velocity sedimentation
through sucrose density gradients. In the presence of Mg
2+,
Figure 3. Mapping of interaction between hFMRP and hCaprin1 in pulldown assays. A) Pulldown assay using 1 mg of the fusion protein
GST-Caprin1 immobilized on beads and in vivo translated
35S-labelled full length FMRP (FL) and its truncated and deleted versions. B) Reverse
pulldown assay using immobilized GST-FMRP incubated with
35S-labeled full length Caprin1 (FL) and its truncated and deleted versions. In both
cases,
35S-labeled Luciferase (Luc) was used as a negative control. C) Schematic diagram summarizing the data presented in A and B. D) Refine region
in FMRP NES (amino acids residues 424–440) required for binding to Caprin1. E) The interaction of FMRP with Caprin1 is stable in the presence of
400 mM NaCl. F) The interaction of Caprin1 and FMRP is direct in a pulldown assay using recombinant proteins.
doi:10.1371/journal.pone.0039338.g003
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sedimenting polyribosomes, and its distribution along the gradient
mirrors that of FMRP (Figure 4). In the presence of EDTA that
dissociates ribosomes into their subunits concomitant with the
release of free mRNP complexes, Caprin1 as well as FMRP were
detected sedimenting in the same fractions. Treatments with
RNase A resulted in the complete destruction of polyribosomes
and mFMRP as well as Caprin1 were displaced to the top fractions
of the gradient. The presence of Caprin1 in polyribosome fractions
was not altered when cytoplasmic extracts derived from KO brains
were analysed, indicating that FMRP is not required for the
presence of Caprin1 with polyribosomal RNPs.
b) Caprin co-localizes with mFMRP in neuronal cell body
and in granules throughout the dendritic branching. To
validate in vivo the potential interaction between Caprin1 and
FMRP, we performed immunohistochemical double staining on
mouse brain cortical sections using IgY#C10 antibody against
FMRP and anti-Caprin1 IgG. Both Caprin (green) and FMRP
(red) labellings were mainly cytoplasmic (Figure 5A), with a weaker
granular signal in the extensions and seemed to co-localize in both
the cell body and neurites.
In order to characterize with more precision the co-localization
of Caprin1 and FMRP in the dendritic branching of neurons, we
double-stained primary cultured rat hippocampal neurons with
IgY#C10 and Caprin1 antibodies. Confocal microscopy showed a
very similar distribution of FMRP and Caprin1 signals. Both
proteins were strongly present in the cell body, and also present in
a granular-like pattern in the dendritic arborization (Figure 5B).
However, at higher magnification, and after deconvolution of the
images, co-localization in neurites appeared weaker than first
thought. The two proteins seemed to be present in a sub-
population of granules distal from the soma (Figure 5C). Binary
merging analyses using the MetaMorphH Software showed a great
range of co-localizations ranging from 4 to 51% over 22 regions
analyzed. Altogether, 23% of Caprin1 and FMRP signals co-
localized in neurites (n=23 neurites, and approximately 3000
granules), however this co-localization seemed highly variable
from one neuron to another.
Figure 4. Caprin1 co-sediments with mFMRP in polyribosomes prepared from total brain and mFMRP is not required for Caprin1 to
associate with polyribosomes. Aliquots containing 10–12 OD at 260 nm were analyzed by sedimentation velocity through sucrose density
gradients in the presence of MgCl2, after incubation with 30 mM EDTA or after treatment with 100 mg/ml RNase A. mFMRP and Caprin1 were
revealed simultaneously with mAb7G1-1. 80S : monosomes ; SS : ribosomal small sub-unit ; LS : ribosomal large sub-unit ; L7 : ribosomal large protein
7.
doi:10.1371/journal.pone.0039338.g004
FMRP-Caprin1 Interactions
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39338Figure 5. FMRP and Caprin1 partially colocalize in somato-dendritic compartments of neurons. A) Immunostainings of mouse brain
cortical sections were carried out using anti-FMRP IgY#C10 (red) and anti-caprin1 IgG (green). FMRP and Caprin1 colocalize both in cell bodies and in
axons of cortical neurons. B) FMRP and Caprin1 colocalize in primary cultured hippocampal neurons. Note that to illustrate staining in neuritis, a high
gain was required resulting in saturation of the fluorescent signal in the cell body. C) The dendritic area from the box in (B) at higher magnification
reveals that only a fraction of FMRP co-localizes with Caprin1. In this selected region, after deconvolution of the high definition images, a total of 453
granules were counted, and colocalization of mFMRP and Caprin1 accounted for only 14%.
doi:10.1371/journal.pone.0039338.g005
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localize in a granular-like pattern in neurites, even though this co-
localization appears to vary across neurons. Moreover, they
indicate that the composition of a given cargo may vary
considerably.
mFMRP and Caprin1 Interactions with Polyribosomes at
High Salts
A requirement to quantitatively immunoprecipitate mFMRP is
the use of high concentration of salt (400 mM NaCl). It is possible
that the epitopes recognized by either mAb7G1-1 or IgY#C10 are
masked and have to be exposed. However, it is not known whether
the high salt regime has any incidence on the sedimentation
properties of FMRP and Caprin1.
a) Sucrose gradient sedimentations. Polyribosomes were
prepared in a standard salt condition at 150 mM NaCl and also
at 400 mM NaCl and analyzed by sedimentation through
sucrose density gradients. In repeated experiments, we observed
that the UV profiles obtained from the two conditions were
similar but not identical, with a slight shift toward the top of the
gradient in the case of the high salt concentration (Figure 6A). At
400 mM NaCl, the 80S monosome was drastically reduced,
while the peaks corresponding to the 40 and 60S ribosomal
subunits were more pronounced, a phenomenon known since the
70’s corresponding to the dissociation of 80S monomers that do
not contain mRNA, referred to as ‘‘vacant 80S’’ [39–41].
Immunoblot analyses of the collected fractions revealed drasti-
cally reduced signals of FMRP and Caprin1 at the level of
polyribosomes, while strong signals accounting for approximately
50–70% of FMRP and Caprin1 were detected at the top of the
sucrose gradients. The same phenomenon was also observed for
FXR1P and FXR2P (see Figure S1). In contrast, the association
of PABP with polyribosomes did not show alteration at high salts
as previously shown [42] and the distribution of the ribosomal L7
protein followed the UV profile. We hypothesized that FMRP
and Caprin1 present in the two fractions at the top of the
gradient could correspond to molecules that are not associated
with mRNAs. We therefore analyzed the distribution of the three
known FMRP-mRNA targets, Fmr1, CaMKIIa and Map1b along
the sucrose gradient under physiological and high salt conditions.
RNA was extracted from each fraction, purified, reversed
transcribed and amplified by qPCR. The results presented in
Figure 6A, representative of two independent gradients, clearly
show that the three FMRP-targets mRNAs tested were all
distributed along the polyribosomal fractions and that only a shift
toward the top of the gradient (one fraction) was observed in the
presence of 400 mM NaCl, as was the case for the UV profile.
In repeated analyses we observed no correlation between the
presence of FMRP and mRNA targets in the top fractions. To
show that FMRP molecules that have been stripped from
polyribosomes under the stringent conditions of high salt
concentrations, were not associated with sedimenting structures,
ultracentrifugation of polyribosomes was extended to 23 hours.
Under these conditions, the 40S small ribosomal subunit was
detected just above the bottom of the gradient. At 150 mM NaCl
condition, trace amounts of FMRP and of Caprin1 could be
detected around 4–5 S resulting probably from released mole-
cules during polyribosomes extraction and manipulations. On the
other hand, after treatment of polyribosomes with 400 mM
NaCl, substantial amounts of FMRP and Caprin1 were detected
in the two fractions at the top of the gradient corresponding to
the loaded volume of the sample that did not penetrate the
gradient and with an S value estimated to be less than 5S.
These results clearly indicate that a substantial amount of
FMRP isolated by immunoprecipitation at high salt regime comes
from molecules that are not associated with mRNAs.
b) Mass spectrometry analyses. In view of the altered
sedimentation properties of mFMRP at 400 mM NaCl, we
wondered whether this observation was a generalized phenome-
non that affected different RNA-binding proteins. Concentrated
polyribosomes were washed with buffers containing either 150 or
400 mM NaCl and after 15 minutes incubation at 4uC, the
samples were recentrifuged at 54,000 rpm (392,540 g) to pellet the
polyribosomes (see Methods section). The pellets were resus-
pended in volumes equal to that of the supernatants, and aliquots
of equal volume were analyzed by SDS-PAGE and the separated
proteins stained with Coomassie brilliant blue. In the 150 mM
NaCl washes, no significant amount of protein was detected, while
at 400 mM NaCl, approximately 15% of proteins were removed
from polyribosomes as calculated after scanning of the stained gels.
To identify the nature of the major polypeptide bands removed
from polyribosomes at 400 mM NaCl, aliquots were analyzed by
SDS-PAGE and the gels cut into 20 sections that were subjected to
trypsin digestion and to analyses by Mass Spectometry. Shown in
Figure 7 is the distribution of identified RNA-binding proteins still
associated with polyribosomes and those removed at 400 mM
NaCl. These results confirm the data presented in Figure 6 (and
Figure S1) as far as they concern the distribution of FMRP,
FXR1P, FXR2P, Caprin1 and PABP. Interestingly, the majority
of RNA-binding proteins were not equally distributed in the two
fractions, for instance RENT1, Ago1, LARP1 and DHX15 were
exclusively present in the polyribosomal fraction resistant to
400 mM NaCl, while hnRNPL2, Stau1, and PAIRB were found
in the salt fraction. Other proteins were distributed in both
fractions. As we had not the intention to establish a catalog of
soluble proteins, these results should be considered as indicative.
Nonetheless, they confirm the results presented in Figure 6
obtained after sedimentation in sucrose density gradients under
high salt concentrations. Given the high number of heterogenous
nuclear RNP proteins present in polyribosomal preparations, we
wonder whether this fraction prepared according to our conditions
could be contaminated by proteins that were released from nuclei
during brain homogeneization. Immunoblot control analyses
performed on the polyribosomal fractions with antibodies to
histone H3 and H2b as well as for RNA-polymerase II indicate
that this was not the case (data not shown).
mFMRP and Caprin1 Neuronal mRNA Targets
In view of the results obtained with mAb7G1-1 that immuno-
precipitates mFMRP and Caprin1, both RNA-binding proteins,
we analyzed a restricted number of mRNAs that have been
reported to be FMRP targets. Among the hundreds of mRNA
obtained either by immunoprecipitation or by AMPRA, we
restricted our choice to few that have been validated such as
CaMKIIa, Map1b, Fmr1, Mbp, Psd95, Gfap, Sod1, Sapap4, and Arc/
Arg3.1 [3,15,16]. In addition, we also tested for CyclinD2 and c-Myc
mRNAs that have been reported to be Caprin1’s targets [43] while
H2A, Ppox and Gapdh mRNA were used as controls. In parallel, we
also immunoprecipitated FMRP with IgY#C10 that do not react
with Caprin1. RNA extracted and purified from immunoprecip-
itated WT and KO2 brain lysates was amplified by RT-PCR with
mRNA-specific primers (Table 1). Total RNA from brain was
used as template for RT-PCR for each tested immunoprecipitated
RNA. Consistent with our suspicions, we observed after agarose
gel electrophoresis and staining with ethidium bromide that Cyclin
D2 and c-Myc mRNA, two mRNAs that have not been reported as
FMRP targets were both immunoprecipitated with mAb7G1-1
FMRP-Caprin1 Interactions
PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39338FMRP-Caprin1 Interactions
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39338Figure 6. Sedimentation of FMRP and Caprin1 in presence of NaCl at physiological and at high salt conditions. A) In presence of
150 mM NaCl, FMRP and Caprin1 are detected associated with polyribosomes. At 400 mM, a clear displacement of FMRP and Caprin1 towards the
top of the gradient is observed, while PABP and the ribosomal L7 protein are not affected. In the bottom panels of A) are shown the distribution in
the sucrose gradients of CaMKIIa, Map1b and Fmr1, FMRP-mRNA targets in the presence of 150 and of 400 mM NaCl. Note the slight shift toward the
lighter fraction in the 400 mM NaCl condition and the absence of mRNA in the fraction containing the highest amount of FMRP at the top of the
gradient. The results are presented as percent of the specific mRNA in each fraction. B) In presence of 400 mM NaCl, the majority of FMRP and
Caprin1 are found as ‘‘floating’’ species in the loading volume that did not penetrate the gradient even after prolonged ultracentrifugation for 23 hrs.
The position of the small ribosomal subunit was determined according to the UV profile and immunoblotting with anti-S6 protein. S values were
determined using purified total RNA from E.coli.
doi:10.1371/journal.pone.0039338.g006
Figure 7. Distribution of RNA-binding proteins in polyribosomes and in salt washes. A) Equivalent volume aliquots from polyribosomes
and from the 150 and 400 mM NaCl washes were analyzed by SDS-PAGE and the separated proteins stained with Coomassie blue. B) Identification by
Mass Spectrometry of RNA-binding proteins present or released from polyribosomes after 400 mM NaCl washes. Poly 400: polyribosomes resistant to
400 mM NaCl; Sup 400: supernatant of the polyribosomes treated with 400 mM NaCl.
doi:10.1371/journal.pone.0039338.g007
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contrast, no signals were observed using IgY#C10. The two next
tested CaMKIIa and Map1b mRNAs showed also a complex
distribution, since they were detected with mAb7G1-1 in both WT
and KO2 immunoprecipitates. On the other hand, using
IgY#C10, CaMKIIa and Map1b were present only in WT
immunoprecipitates. Fmr1, Mbp, Psd95, Gfap, Sod1, Sapap4 and
Arc/Arg3.1 mRNAs seemed to be specifically associated with
FMRP since mAb7G1-1 and IgY#C10 yielded similar signals. In
parallel, we performed quantitative Light Cycler RT-PCR, which
showed similar results, however we noted that CaMKIIa and
Map1b mRNAs immunoprecipitated with IgY#C10 account for
half values obtained with mAb7G1-1 demonstrating that both
FMRP and Caprin1 interact with these targets. Finally, although
the aim of these studies was not to analyze Caprin’s targets, we
tested the presence of Cyclin D2, c-Myc, CaMKIIa and Map1b in
immunoprecipitates with rabbit antibodies against Caprin1, which
confirmed the results obtained with mAb7G1-1 using KO2
extracts (Figure 8B). On the other hand, FMRP targets Mbp,
Psd95 were not detected, as for H2A mRNA.
Discussion
The present study was initiated following the observation that
mAb7G1-1 considered to immunoprecipitate specifically
mFMRP, also reacts with Caprin1, another RNA-binding protein.
We also showed that FMRP and Caprin1 interact independently
of RNA and have defined the regions on each protein that are
necessary for their interaction. During the course of the present
study, Papoulas et al. [44] presented genetic evidence that in
Drosophila, Caprin1 associates with dFMRP to regulate the cell
cycle at the mid-blastula transition (MBT) during embryogenesis
by mediating repression of maternal Cyclin B and activating the
zygotic Fru ¨hstant mRNAs. These results confirm the observation
that absence of Caprin1 results in defects in cellular proliferation
[45]. The authors also reported that dFMRP, Caprin and eIF4G,
a key regulator of translation initiation, were all three immuno-
precipitated with an anti-dFMRP antibody, and suggested that the
complex controls the translation machinery. Puzzling enough,
immunoprecipitations were performed with dFMRP species
detected at the top of the sucrose density gradient used to analyze
polyribosomes, in fractions corresponding to the loading volume,
far away from polyribosomes which were devoid of dFMRP.
While the physical interaction between FMRP and the RNA-
binding protein LARK was reported to regulate eye development
and circadian behavior in Drosophila [46], no functional relevance
has yet been assigned for the interaction of FMRP with the RNA-
binding proteins FXR1P, FXR2P, 82-FIP, NUFIP, MSP58 and
now Caprin1 in mammals. Similarly to FMRP, Caprin1 has been
shown to behave as a translation repressor [31]. In the case of
FMRP, high levels of the protein lead to translational inhibition in
vitro in the rabbit reticulocyte lysate system [47,48]. In addition, in
transfection assays, high levels of FMRP sequester mRNAs into
granule-like structures resulting in repression of reporter genes
[34]. On the other hand, FMRP functioning as an activator of
translation has been documented only recently [49,50]. The two
scenario of FMRP being a translation repressor or activator might
be reconciled if we envision that functions of FMRP depends on its
levels which might vary in subcellular compartments [51]. Indeed
neurons contain autonomous distinct subcellular micro-domains
where translation takes place and mRNAs that have to be
transported at these sites have to be embedded in a compact
ribonucleoprotein structure (or granule) coupled with motor
proteins allowing transport to distances far away from the soma
[23,28,52,53].
One of the most striking observations in the present study is that
Caprin1 binds FMRP in a region that corresponds to the NES
domain. The sequence QLRLERLQID necessary for FMRP to
exit from the nucleus [54] lies precisely between amino acids 422
and 439 where Caprin1 binds FMRP according to our pulldown
assays (Figure 3C). This strongly suggests two scenarios: 1) once
FMRP exits from the nucleus, it can accept Caprin1 as a partner
in the 422–439 region, since the NES is not required once in the
cytoplasm; 2) the FMRP species that bind Caprin1 are not
intended to undertaken any nuclear-cytoplasm shuttling and thus
assemble with mRNP in the cytoplasm. It is worth mentioning that
the majority of FMRP lies in the cytoplasm, while only trace
amounts have been detected in the nucleus [6,55].
As an RNA-binding protein, Caprin1 has been reported to
interact with Cyclin D2, c-Myc [43] and CaMKIIa [31], mRNAs.
Table 1. Oligonucleotides primers used in RT-PCR analyses.
mRNA Primers
Sapap4 F: 59-GGAAGGCTGGTGCTGCCAGATGG-39 R: 59-GGGACATAAATCTCGATGCTGTC-39
Arc/Arg3.1 F: 59-TGAGACCAGTTCCACTGATG-39 R: 59-CTCCAGGGTCTCCCTAGTCC-39
CaMKIIa F: 59-AATGGCAGATCGTCCACTTC-39 R: 59-ATGAGAGGTGCCCTCAACAC-39
Psd-95 F: 59-GTGGGCGGCGAGGATGGTGAA-39 R: 59-CCGCCGTTTGCTGGGAATGAA-39
Fmr1 F: 59-GACAAGTCAGGAGTTGTGAGG-39 R: 59-CTTTAAATAGTTCAGGTGATAATC-39
Cyclin D2 F: 59-GTGGACCCGGTCCGCAGGGC-39 R: 59-CCAGTTCCCACTCCAGCAGCTCC-39
c-Myc F: 59-CTGGTCCTCAAGAGGTGCCACG-39 R: 59-GGGATCTGGTCACGCAGGGCAA-39
Map1b F: 59-CTCCATCCTGCTCACCCACATTG-39 R: 59-GCATAAAATACTGCATTTCCTTG-39
Gfap F: 59-CACGAACGAGTCCCTAGAGC-39 R: 59-TCACATCACCACGTCCTTGT-39
Mbp F: 59-ATAACCATTCCCTGCCTCC-39 R: 59-TCAACCATCACCTGCCTTC-39
Sod1 F: 59-GCAGGACCTCATTTTAATCCTCACT-39 R: 59-AGGTCTCCAACATGCCTCTCTTC-39
Gapdh F: 59-CTTCATTGACCTCAACTACATG-39 R: 59-CACAGTCTTCTGGGTGGCAGTG-39
H2a F: 59-GGCCCGCGCCAAGGCCAAG-39 R: 59-CTCGTCGTTGCGGATGGCCAG-3
Ppox F: 59-CAGTTTTGCCCAGCGCCGCC-39 R: 59-GTCAGCCTCCAGACTGCTGTC-39
doi:10.1371/journal.pone.0039338.t001
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from the KO mouse, indeed show the presence of these mRNAs.
It is reasonable to conclude that some mRNAs might be common
targets of Caprin1 and FMRP. Whether the two proteins bind to
the same RNA molecule or that they function individually is not
known. Consistent with our observations that mAb7G1-1 has an
additional specificity for Caprin1, is the fact that RNA is
immunoprecipitated from FMRP KO brain extracts (see
Figure 2A in ref. 15). The substraction of immunoprecipitated
RNA from KO from the WT-IP as was done by Brown et al. [15]
might have introduced a misestimation of the levels and the nature
of FMRP RNA targets in the case of mRNAs common to FMRP
and Caprin1.
We also have clarified the observation that high salt treatment is
required to allow immunoprecipitation of FMRP. It seems that
FMRP is embedded in a structure that is not available neither to
the monoclonal antibody 7G1-1 nor to the chicken IgY #C10 (as
well as to other IgY from the same generation; unpublished
results). Approximately 50 to 70% of FMRP present on
polyribosomes are removed by high salt treatments and behave
as free proteins or protein complexes. It is well established that in
addition to its RNA-binding properties, FMRP also behave as a
protein-protein adaptor to form homo-and hetero-dimers [56].
Whether these non-RNA binding species function as repressors or
activators of translation is not known. The remaining 30 to 50% of
FMRP was constantly found associated with polyribosomes and
we propose that they represent the bone fide RNA-binding
molecules.
Recent results from Darnell et al. [19] revealed an unexpected
mode of FMRP-RNA interaction. No specific RNA motifs were
identified by in vitro FMRP-RNA selection experiments and it
seems that FMRP lays all over the coding sequences of the target
mRNAs studied. In addition, previous studies have shown that the
RGG box, thus the binding site to the G-quadruplex, is not
essential for total FMRP to associate with polyribosome
[21,57,58]. Although highly speculative, we propose that FMRP
might function at two different levels : FMRP species that do
interact with RNA and a second species that are protein adaptors
interacting with different RNA-binding proteins in contact with
RNA. Post-translation modifications might govern the fate and
functions of FMRP towards these two avenues. As a working
hypothesis, we propose that the high salt treatment, as used in the
present report, removes the FMRP sheath from stalled polyribo-
somes leaving in place the FMRP species that have high affinity to
mRNA targets.
In summary, we have shown that Caprin1 is a new FMRP
interactor. Similarly to FMRP, Caprin1 is able to bind mRNA and
is associated with the cytoplasmic translation apparatus and in
trafficking granules in dendrites. Whether Caprin1 binds to FMRP
to regulate its conformation (or vice versa) or has a synergistic
effect, such as reported for FXR1P and FMRP [59], remains to be
shown. As the world of RNA-binding proteins is expanding,
understanding the role of Caprin1 and of other RNA-binding
FMRP interactors, will be essential to unravel the functions altered
by lack of FMR1 expression in the fragile X syndrome. Since the
absence of both FMRP and Caprin1 have been reported to induce
dendrite dysmorphogenesis, it will be highly interesting to generate
Fmr1/Caprin1 double knockout mice to study whether Fmr1 and
Caprin1 gene products interact or complement with each other.
Finally, since mAb7G1-1 does not react with human FMRP, we
consider it as an excellent monoclonal antibody to study Caprin1
in human cells.
Materials and Methods
Ethics Statement
Mice were bred in our animal facility and treated following
the guidelines of the Canadian Council on Animal Care. This
Figure 8. mRNAs associated with Caprin1 and FMRP. A) mRNAs co-immunoprecipitated by mAb7G1-1 and IgY#C10 from WT and KO brain
extracts were analyzed by RT-PCR and visualized by agarose gels (left panels) and by Light Cycler RT-PCR (right panels). Bars in red refer to mRNA
targets to Caprin1, in blue common to Caprin1 and FMRP, in green to FMRP and in black to non-targets mRNAs. Dark colors refer to WT and pale to
KO, respectively. N=5, P#0.001 of a pool of 10 adult brains. Vertical black dot lines represent thresholds corresponding to background. B) RT-PCR
analyses of selected mRNAs co-immunoprecipitated with Caprin1.
doi:10.1371/journal.pone.0039338.g008
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Cell Cultures and Animals
HeLa S3 and NIH 3T3 cell lines were purchased from ATCC,
and STEK Fmr1
2/2 KO cell line was established as described
previously [34]. Cells were propagated and maintained in DMEM
supplemented with 10% FBS and antibiotics (100 units/ml
penicillin, 50 mg/ml streptomycin). Primary neuron cultures were
prepared from neonatal rat hippocampi as described [60]. Wild-
type C57BL/6J and Fmr1
2/2 KO2 strains [32], obtained from
David Nelson, Baylor College of Medicine, Texas, USA, were
bred in our animal facility.
Protein Studies
Antibodies. IgY from egg yolks were purified using the
Eggcellent
TM chicken IgY purification kit from Pierce. mAb7G1-1
[15] was affinity purified from the hybridoma supernatants using
mFMRP immobilized on nitrocellulose membranes and the non-
adsorbed remaining supernatant considered as IgG depleted.
Immunoblot analyses were performed using hybridoma superna-
tants from mAb1C3 [5] and mAb7G1-1 [15] to FMRP, affinity
purified rabbit IgG directed against Caprin1 were from [30], and
Proteintech Group, affinity purified rabbit anti Ago2 (Cell
Signaling), rabbit polyclonal anti-PABP (Cell Signaling), rabbit
anti-L7 ribosomal protein (Novus Biologicals), rabbit anti-S6
ribosomal protein (Cell Signaling). Other antibodies used but not
shown were rabbit anti-H3ABC, mAb14C8 anti-H2b and
mAbCC3 anti-RNA polymerase II (obtained from Jacques Co ˆte ´,
Robert Tanguay and Michel Vincent, respectively). Detection of
bound antibodies was performed with HRP-coupled secondary
antibodies followed by ECL reaction.
For simultaneous double-immunoblot analyses, the Odyssey
Infrared Imaging System from LI-COR was used. A mixture of
mAb7G1-1 and rabbit antibodies against Ago2 was reacted with
the membranes and revealed simultaneously with anti-mouse IR-
Dye 800 (green) and anti-rabbit ID-Dye 700 (red) secondary
antibodies (LI-COR). The two colors were imaged simultaneously
in a single scan.
Immunofluorescence and histochemical analyses. Brain
sections and hippocampal neurons grown on coverslips were
processed as described [22,23]. Samples were mounted in Prolong
Gold medium (Invitrogen). Images were captured using a Zeiss
LSM 510 confocal microscope and a 6361.4 NA objective and
analysed using the MetaMorphH Software.
Polyribosome preparation and analysis. Total brain
polyribosomes were prepared from 10 days old wild-type
C57BL/6J and Fmr1
2/2 KO2 mice, and analyzed as described
[7]. For prolonged sedimentation in sucrose density gradients,
samples were centrifuged at 34 000 rpm (198,045 g) for 23 hours
in a SW41 rotor, and S values calculated using E.coli total RNA.
Polyribosomes washed with 150 mM or 400 mM NaCl were
concentrated by ultracentrifugation at 54 000 rpm (392,540 g) for
2 hours in 0.8 ml polyallomer tubes fitted in the Beckman SW 60
Ti bucket using a Delrin adapter (Seton, CA).
Immunoprecipitation. Affinity purified mAb7G1-1,
IgY#C10 and affinity purified anti-Caprin1 were used in
immunoprecipitations assays. For protein studies, immunoprecip-
itations of mFMRP were performed according to the protocol of
Brown et al. [15] with the exception that BSA was omitted from all
solutions. For RNA analyses, we applied the Brown protocol with
no modifications.
Proteomics analyses. Analyses were performed at the
McGill University-Genome Que ´bec Innovation Centre facility
(Montre ´al). Samples were run on SDS-PAGE, the gels were
stained with Coomassie blue, scanned, and analyzed using the
IMAGEMASTER software (Amersham Pharmacia). Gel slices
were excised, proteins were in situ digested with trypsin, and the
resulting tryptic peptides analyzed by mass spectrometry. Ob-
tained sequences were interpreted with the Scaffold 3 Search
program.
GST-pulldown assays. Coding sequences for FMR1 iso7
and Caprin1 were cloned into pGex-4T-1 (Amersham). Fusion
proteins were expressed in BL21(DE3) E.coli strain (Stratagene)
grown in liquid LB until OD$1 and induced overnight with
1 mM IPTG. Bacteria were then collected and the expressed
fusion proteins purified in non-denaturing conditions on glutathi-
one-Sepharose beads, according to the manufacturers’ protocol
(Amersham Pharmacia Biotech). Fusion protein was eluted from
the beads with 10 mM reduced glutathione in 50 mM Tris-HCl
(pH 8.0). Protein yields were estimated by Coomassie staining
using as standard different concentrations of BSA ranging from 0.2
to 1 mg/ml. FMRP and Caprin1 and their truncated variants (see
below cDNAs contructs) were produced by in vitro transcription-
translation in rabbit reticulocyte system in the presence of [
35S]-
methionine (Amersham) according to the manufacturer’s instruc-
tion (Promega, Madison, WI). 5 mlo fin vitro-translated proteins
were mixed either with 1 mg of GST-FMRP or with GST-Caprin1
bound to beads and incubated 2 hr, at room temperature, under
constant rotation in 500 ml of pulldown buffer (10 mM Tris
pH 7.4, 150 mM NaCl, 0.5% NP40, Protease Inhibitor Cocktail,
Roche). Beads were collected by spinning (5,000 rpm, at room
temperature for 2 min.) and washed 4 times with the pulldown
buffer. Final wash was removed and beads were resuspended in
50 ml of SDS-sample buffer. One third of the sample was loaded
on a 7.5% SDS-PAGE. Gels were dried and exposed to Super RX
films (Fuji).
cDNA Contructs
All FMR1 constructs used in the present study were described
elsewhere [21,22]. For CAPRIN1 constructs, pGEX-hCAPRIN1
plasmid [30] was digested by BamHI, and the resulting 2142-pb
fragment subcloned into the pTL1 vector to generate pTL1-
hCAPRIN1. Other constructs were generated by digestion of the
pGex-hCAPRIN1 by EcoR1/BamH1, and by HindIII/Pst1 and
the fragments subcloned into pTL1 plamids to generate pTL1-
hCAPRIN1 (1–189) and pTL1-hCAPRIN1 (75–267), respectively.
For the other constructs, pTL1-hCAPRIN1 plasmid was used as a
template for PCR using as a standard the primer the T7
oligonucleotide forward 59-TAATACGACTCACTATAGGG -
39. CAPRIN1 (1–146) was generated using reverse 440R: 59-
CGTTTCTGTTCAGCTTCTTCTC-39; CAPRIN1 (1–203) with
reverse 619R: 59-CATTCAACCTCAAGCTCATGTC-39; CAP-
RIN11 (1–271) with reverse 813R: 59- TCAACTGCAGGTGCT-
GAGG-39; CAPRIN1 (1–349) with reverse 1047R: 59-ATT-
CACTGGAGTCAAAGAGTGG-39; CAPRIN1 (1–436) with
reverse 1308R : 59-ATTCAAAGGAACCTGTGTCGCT-39;
CAPRIN1 (1–498) with reverse 1494R : 59-ATTCCCAGCCT-
GAAATACTTGA-39; and CAPRIN1 (1–600) with reverse 1799R:
59-ATTGGAAATCCAGTGTTCTGCTGAG-39.
To generate deletion mutants, pTL1-hCAPRIN1 plasmid was
used as template for PCR-mediated plasmid DNA deletion
method. Primers were constructed to amplify the entire sequence
of the plasmid except for the specific region that is to be deleted.
The 59 ends of the primers include the cutting sequence of the
restriction enzyme EcoRI or PstI with one adjacent base at the 59
and 39 ends to facilitate the digestion close to the end of DNA
regions. The sequences of the primers synthesized were:
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AACTGCAGGTTCCACATACAGGT-3;
D245–267:59-CAGCACCTGCAGTTGAAGA-39,5 9-
AACTGCAGGACTGAAAAACACGC-39;
D230–267:59- AACTGCAGGTTCCACATACAGGT-3 , 59-
AACTGCAGTTTTCCTTCCCTTCC-3;
D215–267:59-CAGCACCTGCAGTTGAAGA-39,5 9-
AACTGCAGTGAATGGAGGCATGT-39;
D186–216:59- CTTATAGAATTCATCCAAC-39,5 9-GAT-
GAATTCGTGGGACCTGCTGGA-39.
cDNA Synthesis, RT-PCR, and LightCycler Real-Time PCR
RNA immunoprecipitated by mAb7G1-1, IgY#C10 and anti-
Caprin1 were extracted using the Trizol reagents according to the
manufacturer’s protocol (Invitrogen). Reverse transcription using
random poly dT primers (Invitrogen) and Sensiscript (Quiagen)
was performed on 1 mg of RNA and one fifth of the resulting
reaction was used for PCRs with 100 nM of the oligonucleotides
primers listed in Table 1. PCR were performed by initial
denaturation at 95uC for 5 min, followed by 35 cycles of
denaturation at 95uC for 10 sec, annealing for 20 sec at 65uC,
extension at 72uC for 30 sec and a final extension step at 72uC for
5 min. Amplified DNA fragments were fractionated on 1%
agarose gels and stained with ethidium bromide.
Real-time PCR was performed with a LightCycler (Roche)
using SYBR green chemistry (Ambion). The ratio and levels of
different generated samples were calculated using the Light Cycler
Data Analysis Software (Roche Molecular Biochemicals).
For analyses of mRNA present in polyribosomes, fractions
obtained from sucrose gradients were extracted using the Trizol
reagents. The purified RNA was subjected to reverse transcription
and qPCR as detailed above. For each mRNA studied,
normalization to three internal controls (Gapdh, H2A and Ppox)
was performed and polyribosome fractions were plotted as
percentages of the total amount of the mRNA in the collected
fractions. All analyses were performed in triplicates.
Supporting Information
Figure S1 Sedimentation of FXR1P and FXR2P in
presence of 150 and 400 mM NaCl. For details see Figure 6
in the main text.
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